SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Mar 28, 2019
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: March 28, 2019 · CIK: 0001513525 · Accession: 0001213900-19-005166
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230470
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Mr. Jeffrey Gabor Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No: 333-230470
Dear Mr. Gabor:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-230470), be accelerated by the U.S. Securities and Exchange Commission to Monday, April 1, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911
March
28, 2019
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No: 333-230470
Dear Mr. Gabor:
Adial Pharmaceuticals,
Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement
on Form S-1, as amended (File No. 333-230470), be accelerated by the U.S. Securities and Exchange Commission to Monday,
April 1, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The
Registrant hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request
for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions
you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
By:
/s/ William B. Stilley
III
Name:
Title:
William
B. Stilley III
Chief Executive Officer
cc:
Joseph
Truluck, Chief Financial Officer, Adial Pharmaceuticals, Inc.
Leslie
Marlow, Esq., Gracin & Marlow, LLP